{
  "docId": "019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "docSlug": "4fd785179c9b78e08eb8c823d8e306e6",
  "documentTitle": "argenx SE | Results Presentation Deck | 24 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 24,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The chart shows a positive correlation between IgG reduction and MG-ADL improvement. The right side details the clinical trial design for the SC formulation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f8c0-72fa-b47b-4b134ca99d3b/5",
  "deckHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "deckJsonHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b.json",
  "deckAnchorHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Correlation between IgG reduction and MG-ADL change",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8072aec-1e54-4edb-8560-0f96d7be6d28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.83,
        "y": 0.02
      },
      "kind": "image",
      "text": "adapt myasthenia gravis study logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acf53c47-042f-4a58-8765-015ede292213",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.38
      },
      "kind": "list",
      "text": "Study designed to demonstrate non-inferiority of PD effect of 1000 mg SC efgartigimod to 10mg/kg IV efgartigimod. Phase 1 HV data showed 1000 mg SC efgartigimod has similar PD effect. Additional patients from ADAPT+ to transition. Primary endpoint at day 29.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0996021c-b425-4c1a-a7bd-eff89db882d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "SC Bridging Strategy Leverages Correlation Between Pharmacodynamic and Clinical Effect",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "408777a0-923a-4ae8-bf35-37bd18238b11",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 5,
      "beatId": "14f2a1bd-eacd-4305-b248-ea3710f3a72b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 5-10 present Efgartigimod as a solution.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}